Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 631-639

  Olsson Strömberg, Ulla ^a   Åleskog, Anna ^a   Björnberg, Anneli ^a   Höglund, Martin ^a   Simonsson, Bengt ^a   Bengtsson, Mats ^a   Barbany, Gisela ^a   Larsson, Rolf ^a   Lindhagen, Elin ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic myeloid leukemia; Drug combinations; Fluorometric microculture cytotoxicity assay; Imatinib mesylate; In vitro drug sensitivity

Indexed keywords

AMSACRINE; ARSENIC TRIOXIDE; CISPLATIN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HOMOHARRINGTONINE; IDARUBICIN; IMATINIB; INTERFERON; MELPHALAN; MITOXANTRONE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL CRISIS; BLOOD; BONE MARROW; CELL LINE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; FEASIBILITY STUDY; FLUOROMETRIC MICROCULTURE CYTOTOXICITY ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BLAST CRISIS; CYTARABINE; DAUNORUBICIN; FEASIBILITY STUDIES; HARRINGTONINES; HUMANS; INTERFERONS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; OXIDES; PIPERAZINES; PYRIMIDINES; VINCRISTINE;

EID: 33747605541     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000217423.59831.db     Document Type: Article

References (47)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82:691-703.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315:550-554.
3. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-830.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-1082.
5. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave P, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984; 1:665-668.
6. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343:1486-1488.
7. Gale RP, Grosveld G, Canaani E, Goldman JM. Chronic myelogenous leukemia: biology and therapy. Leukemia 1993; 7:653-658.
8. Goldman JM. Optimizing treatment for chronic myeloid leukemia. N Engl J Med 1997; 337:270-271.
9. Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta Haematol 2005; 113:155-162.
10. The Italian cooperative study group on chronic myeloid leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-825.
11. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345:1392-1397.
12. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114:532-538.
13. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064-4077.
14. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 1995; 92:2558-2562.
15. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-104.
16. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
17. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-1937.
18. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
19. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96:3195-3199.
20. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002; 94:2653-2662.
21. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197:461-463.
22. Weisenthal LM, Dill PL, Kurnick NB, Lippman ME. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983; 43:258-264.
23. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69:615-632.
24. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50:177-185.
25. Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6:1121-1128.
26. Nygren P, Hagberg H, Glimelius B, Sundstrom C, Kristensen J, Christiansen I, et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay. Ann Oncol 1994; 5 (Suppl 1):127-131.
27. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122:376-385.
28. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15:342-347.
29. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97:1999-2007.
30. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505.
31. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000; 46:913-920.
32. Larsson R, Nygren P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res 1993; 13:1825-1829.
33. Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 1990; 4:567-571.
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
35. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5:85-91.
36. Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Cancer Genet Cytogenet 2001; 131:125-134.
37. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999; 35:424-432.
38. Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, Nygren P, et al. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 1997; 76:211-219.
39. Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 2004; 73:407-411.
40. Aleskog A, Hoglund M, Pettersson J, Hermansson M, Larsson R, Lindhagen E. In vitro activity of the flt3-inhibitor SU5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia. Leuk Res 2005; 29:1079-1081.
41. Hallbook H, Barbany G, Aleskog A, Bjornberg A, Larsson R, Sundstrom C, et al. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. Anticancer Drugs 2005; 16:631-634.
42. Zwaan CM, Kaspers GJ, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wunsche R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000; 96:2879-2886.
43. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8:2167-2176.
44. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530-3539.
45. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16:2349-2357.
46. 3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001; 15:772-778.
47. Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn AF, et al. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. Semin Hematol 2003; 40:92-97.